CDMO LEADERSHIP AWARDS 2024

KEIR LOIACONO
CEO
BlueSphere Bio

MARCH 2024

A Lawyer Brings Order to Cell Therapy Outsourcing

p. 6

PRESENTED BY: OUTSOURCED PHARMA | LIFE SCIENCE CONNECT

RESEARCH CONDUCTED BY: ISR reports — Smarter questions ∴ Smarter answers

When you
think equipment,
think **Federal Equipment**

THINK SHORTER LEAD TIME

PHARMA
CHEMICAL
PLASTICS/ RUBBER
PACKAGING
FOOD & BEVERAGE
TRAINING
UTILITIES

Federal Equipment Company has on-hand inventory in more than 200 categories, enabling you to source reliable processing and packaging equipment that's housed in clean, climate-controlled warehouses. We obtain most of our inventory by providing asset management programs to large, multinational companies. This gives you a wide range of options to get the leading OEM-brand equipment you need from a reputable source, and installed and operating in your facility as fast as possible. No matter what your equipment needs are, make Federal Equipment Company your first call.

+1 877 536 1509 > www.fedequip.com

Federal Equipment Company

Contents

@OutsourcedPharm | linkedin.com/showcase/outsourced-pharma/ | facebook.com/Outsourced Pharma | WWW.LIFESCIENCECONNECT.COM

CDMO LEADERSHIP AWARDS 2024

A Year Of Questions Answered With Solutions

LOUIS GARGUILO
Chief Editor, *Outsourced Pharma*

Looking back on 2023, an overall assessment might spring from the thought that the year began with a slew of questions that were industrywide and sector-specific, national and global, and micro- and macroeconomic. Overlapping all those questions for us were these two: Are we finally over the COVID supply-and-demand shocks? Can we keep up with the increasing pace of scientific and technological advancements? The companies best positioned to deal with those two are contract development and manufacturing organizations (CDMOs).

Collectively and by-and-large, we can posit their replies over the past 12-plus months. Demonstrated in labs and facilities where CDMOs plied their trade on behalf of a growing customer base, the answers have been, "Yes, we have turned the corner," and, "Yes, we can handle expanding customer needs." Even if there were lingering challenges (and there were), CDMOs were determined to work them out with you — the various drug and therapy sponsors across our broadening biopharma industry. The best at meeting these changing circumstances and overcoming persistent challenges are those you will find in this 2024 edition of the *CDMO Leadership Awards*.

Still, that first half of the year was worrisome. I could hear it in the voices of the bio and pharma executives I interviewed for my publication, *Outsourced Pharma*. Our readers entered the year trying to gain a focus on a still blurry picture of capacity and costs, timely CDMO access, worker availability, and skillsets. Sponsors were introducing emerging technologies and new modalities (e.g., RNA innovations, oligonucleotides, varying cell therapies, and some historic gene-therapy advancements — and approvals).

Thankfully, while you were wrestling with uncertainties and advancing programs through the development and manufacturing phases quicker than ever before, throughout the year the CDMO industry was there with you, hard at work, adapting to your demands and evolving externalities, and adjusting internal operations and management. Your CDMOs may not have had all the answers, but they did offer solutions. And CDMOs providing solutions in the face of uncertainty and change have been key to your success. Yes, with some rough edges (e.g., lingering capacity/shortages in some areas, longer start times and higher costs in others), sponsors were able to meet most of your goals through outsourcing and external partnerships. Our awards are testaments to those CDMOs who are best at helping you prevail, and this list of achievers provides you a leading indicator of your future success.

It's an honor to provide readers with this 2024 edition of the *CDMO Leadership Awards* issue and a privilege to congratulate the winning CDMOs. Award winners were determined by you and your industry compatriots — assessed via your direct experiences — as the most trustworthy partners. Your questions, we might say, were answered best by their solutions — the services they provided and the materials and products they delivered.

To determine our best-in-class service providers, Industry Standard Research (ISR) meticulously surveyed and interviewed biopharma customers in key areas, such as service, reliability, quality, and many more. Thank you to those who participated in the survey; you provide the ultimate significance of these awards — still the most significant awards in our outsourcing industry. Finally, my personal appreciation to Keir Loiacono, Esq., CEO of BlueSphere Bio, for working with me as this year's cover feature. Thank you again to all our readers, and on behalf of all my colleagues at *Outsourced Pharma* and Life Science Connect, congratulations to the 2024 CDMO Leadership Award winners.

OUTSOURCED PHARMA

MARCH 2024 CDMO LEADERSHIP AWARDS

LIFE SCIENCE CONNECT
5340 Fryling Rd., Suite 100
Erie, PA 16510-4672
Telephone: 814-897-7700

WWW.LIFESCIENCECONNECT.COM

CEO
Jon Howland / 724-940-7555 / Ext. 171
jon.howland@lifescienceconnect.com

CHIEF EDITOR
Louis Garguilo
louis.garguilo@lifescienceconnect.com

CONTRIBUTING EDITOR
Michelle Raley
mraley@vertmarkets.com

VP OF BUSINESS DEVELOPMENT
Dave Lanahan / Ext. 283
dave.lanahan@lifescienceconnect.com

DATA ANALYTICS
Rick Miller
rick.miller@lifescienceconnect.com
Kevin Morey
kevin.morey@lifescienceconnect.com

Millipore®
CTDMO Services

MilliporeSigma

Built to Serve

your Milestones. your breakthroughs.

Our CDMO expertise in development and manufacturing, coupled with contract testing from pre-clinical to commercial, across multiple modalities accelerates client success.

We are the industry's experienced CTDMO choice — built to serve and honored to receive the 2024 CDMO Leadership Award.







SigmaAldrich.com/MilliporeCTDMO

Contract Testing Development Manufacturing Organization Services



KEIR LOIACONO
CEO
BlueSphere Bio

A Lawyer Brings Order to Cell Therapy Outsourcing

LOUIS GARGUILO Chief Editor, *Outsourced Pharma*
LouisGarguilo@LinkedIn

As we steer our conversation to working with CDMOs, Keir Loiacono interjects, "I always say I've brought a little New Jersey litigator to Pittsburgh biotech." Today, his attorney-educated focus is practiced from within that city of bridges as CEO of BlueSphere Bio, an emerging biotech focused on T-cell receptor (TCR) technology.

"I learned as a lawyer if you have a 'bet-the-company' trial coming up, you never have enough time," he says, "so you need people in the trenches as hyper focused, and almost obsessive about attention to detail, as you are." With that attitude and a solid team in place, when there is an unexpected occurrence, "which can happen in a courtroom or any day in cell therapy development and manufacturing outsourcing, you've set the cadence to take action quickly."

Loiacono isn't quite advocating for "litigating" your CDMOs — as we'll see, he considers them vital partners, critical to the success of the entire industry. But he does have stringent insights on how to keep everyone motivated and on alert. He says more than once during our discussion, "Nobody cares as much about your objectives as you; it's your team who needs to closely manage the relationship with your external partner."

A Supporting Bench

BlueSphere is located in a new high-rise that houses its headquarters, which includes wet labs for research and discovery based on the company's proprietary TCR platform and significant process development capabilities. It outsources all of its cell manufacturing needs and also utilizes vendors for scaled development and testing assistance. BlueSphere is the first translational sciences stand-alone company formed by UPMC Enterprises, the venture capital arm of the Pittsburgh-based health system.

Founded in 2017, BlueSphere utilizes proprietary technology platforms for novel T-cell therapies aimed at hematologic malignancies and solid tumors. Surpassing CAR-T solutions today, the thinking is that TCRs will be more effective in treating various cancers, and with fewer side effects. Although BlueSphere's initial focus is hematologic malignancies, the company is also developing product candidates for solid tumor indications. BSB-1001, targeting the minor histocompatibility antigen-1 (HA-1), is its first TCR-based T-cell clinical candidate for the treatment of high-risk leukemias, including acute myeloid leukemia (AML). The company submitted its first IND, for the BSB-1001 therapy, during the first quarter of 2024, and anticipates opening a first-in-human clinical trial for BSB-1001 later in the year.

Loiacono became CEO in 2022 to lead BlueSphere into its next phase of growth. He has built a strong management team with industry veterans, including chief development officer Bob Keefe, Erkut Bahceci as chief medical officer, and Kim Jaffe as senior vice president of business development and strategy. Among some 40 employees overall, the company has technical expertise in research, discovery, and product development. While key product development activities are performed in-house by BlueSphere's experienced team, Loiacono estimates 95% of "making the product" takes place at a handful of major CDMOs. One of those service providers is a plasmid manufacturer; another does the gene editing required for BioSphere's products; a third supplies gene-editing materials, and, says Loiacono, "We're using lentiviral transduction, so we have a company that does that for us." All these components "get shipped to our cell therapy manufacturer," where the actual BSB-1001 product is then made. With the exception of BlueSphere's lentiviral vector manufacturer in Europe, current external partners are U.S.-based. "My team and I have used vendors in China in the past — and there are some very good ones — but right now we're not using anybody there," he clarifies.

BSB-1001 requires a complicated supply chain with multiple moving parts that need to be coordinated. Emerging companies without experience in this arena would be seriously challenged trying to manage similar development and manufacturing needs. "There's this thought that what makes a successful biotech is the underlying technology and discovery capabilities, and that is what gets people excited initially," says Loiacono. However, he says, "The organization's ability to actually succeed in the clinic is all about operational execution. If you can't execute every step in the cell therapy world, getting new therapies to patients is impossible."

The keys, he says, are tenacity, working 24/7 to oversee each aspect of the business, and having dedicated and smart people working alongside you. He mentions his chief development officer held senior positions at two CDMOs and a cell therapy operation at a Big Pharma. His head of operations is "a brilliant project manager, but also a Ph.D. scientist who ran R&D at a clinical-stage biotech." They may not be lawyers, but they know what it takes to execute on cell therapy contracts. "You have to have that internal bench with different expertise and perspectives," says Loiacono. In other words, what's on your inside goes far to determine what happens on your outside.

CDMO Resources

Loiacono says the "traditional biotech model" is an attempt to maintain a handful of employees, and perhaps grow slowly as programs move out of discovery and into product development. "What do these companies do in that case?" he asks rhetorically. "They pick one of the CDMO names we've all heard of, invest significant capital and resources, and hope that provider is going to execute." But that rarely happens so smoothly in development and manufacturing. Challenges arise, and delays occur — sometimes putting biotech startups out of business. "So it's a hypervigilant managing of the outsourcing processes that's necessary, both internally and externally."

Internally because even prior to working out the logistics of a program with a CDMO, Loiacono focuses on getting his own house in order. He describes how his project management and operations teams work side-by-side with the development, clinical, and manufacturing teams. "On your side as the sponsor, you need integration — people working together toward the common objective," he advises. "And I believe cell therapy is more complicated than many other areas of drug development — it is wrought with complications and obstacles." Thus, when Loiacono took over as CEO in October of 2022, among his initial priorities was to improve the internal organization at BlueSphere. "At that time, we didn't have a manufacturing process we knew we could move forward with, let alone think about an operational plan to file an IND," he recalls. "The first thing I did was focus on allocating team members toward our intentions." Next, he hired "the best regulatory team I could find, whom we pay a lot of money for." Today, he believes he is staffed appropriately with CMC, project management, regulatory, and clinical resources in order to answer this vital question: What are all the steps that have to happen to outsource successfully? That question should be addressed "before going out and communicating to CDMOs and other external partners." CDMO performance, Loiacono says, will only be as good as the information the sponsor feeds them. "Communication around expectations and goals is our responsibility. Communication at BioSphere starts ahead of transfer to a CDMO, with three or four separate meetings at regular intervals."

These meetings are akin to multidisciplinary "working sessions" and are followed by correspondence with the CDMOs to relay information and data and strategic direction. "Equally important," he adds, "this early correspondence is used to understand communication from the CDMOs — to see where they stand with their activities and deadlines." Currently, some 10 BlueSphere employees are "mostly dedicated" to overseeing the CDMO relationships, and, says Loiacono, "We centralize all of our project management and utilize app-based software." A project's status and needs get updated in real time. Often, he'll have a person-in-plant at a CDMO facility for important manufacturing runs. These professionals "partner with our cell therapy manufacturers, and I'll add they have been very good partners to us."

Inside The CDMOs

While Loiacono speaks positively about his external relationships and the general state of our outsourcing industry, he never sheds his tenacity for execution, detail, and improvement. "I'm a lawyer by training, worked as a general counsel, and have managed multiple law firms in complex litigations at public companies," he begins, as he expands on his background and mindset.

"I learned early in my career the only way you're successful is if you manage your people and nurture your relationships with partners," he says. "That's not because they're not good. In fact, overall they are excellent. But you as senior executive are in charge of priorities and timelines." Regarding his own role as chief executive, he adds, "No one watches the clock like the CEO of a biotech where investors think in terms of burn rates, inflection points triggering further investments, and time frames for ultimate return on those investments." A six-month delay at a CDMO may sound like a standard predicament in today's outsourcing world, but Loiacono knows "a delay of that kind can actually bankrupt an emerging biotech." The even bigger concern to Loiacono, who is a cancer survivor himself, are the patients. "While success and building shareholder value are critical to our survival, the real ticking clock is for our patients. We have a moral and ethical obligation to execute with unfettered intensity. That is our mandate," says Loiacono.

And that should also be the mandate of external partners. To better ensure it is, Loiacono says BlueSphere employees are "inside" their CDMOs, managing every step of the way. "We tell them up front that we will be hands on. I actually think that's a good way to pick the right partners. We select and view our CDMOs based on the way we operate." While he views CDMOs as partners, he says those partners need to understand that BlueSphere has its own skilled MD and Ph.D.-level product development, operations staff, and project managers. "You are going to have challenges in manufacturing. That's important for your readers to hear," he says. This is drug development, and that's the way it is. There's no such thing as a perfect manufacturing run.

Loiacono likes to "set the stage with the heads of the CDMOs." As the CEO of his company, he gets on the phone with the COOs and the CEOs at the CDMOs when there are critical issues that are not being handled the way he wants them to be. "These are patients' lives we are ultimately talking about; we're not making lifestyle drugs," he says with rising emotion. "Our patients are sick and have poor prognoses. Oftentimes they are out of options." The intensity Loiacono and team bring leads to big-picture and fundamental questioning at every step of the outsourcing process. For example:

- Are the CDMOs' cleanrooms and GMP facilities exceptional? Do they have backup generators?
- Is the staff experienced and well trained? Who are their day-to-day contact people, and are they responsive?
- How have our audits gone?
- Are they experienced in clinical trial material shipment?

"Without knowing and living in every aspect, you can't be sure of your execution," he says. "Once you get to the clinic, that's your performance. You are in the courtroom and on stage. So, strive for perfection."

You Don't Need To Be A Lawyer

Finally, it's important to point out that Loiacono believes it's not the lawyer in him from which he is driven but his "fundamental makeup" that brings the drive to whatever profession or position he's occupied.

Some people are simply born, shall we say, with a certain energy. It's often said executives need to be driven — and that sense of drive comes from something inside each individual. Loiacono started his career working in emergency management services (EMS), as an EMT. "I did that through college," he says with visible pride. "You and your partner are 40 minutes from a hospital, taking care of a patient. It's attention to detail, it's time oriented. It's understanding what the objectives are and being focused, but being able to be fluent in a situation." Years later, he launched a sales force in pharma, where he worked in med device sales, and helped build a company that was sold to J&J. Then he became a lawyer ... and now the CEO of BlueSphere.

"Look, if you're in sales, your number is your number," he says. "I probably shouldn't say it this way, but 'you eat what you can kill.' Yes, being a lawyer gave me a certain skillset, but I think I was always programmed this way. People don't care about excuses. There's a bottom line, and that's what drives revenue. It's just my mentality of being in these situations."

Today, he makes clear that, unequivocally, it's the patients to whom he is devoted. Second are the employees and investors who enable the delivery of new medicines to those patients. And then there is the activity of outsourcing and the relationships with CDMOs and all external partners. Loiacono wants other drug and therapy developers to ensure they come at that final element of the equation with equal gusto. "A win for me as a CEO is putting a new, safe medication into a patient who didn't have that option before." And everyone involved has to play their part.

CAPACITY NOW AVAILABLE

Want the Best APIs? Work with the Best!

World-class API development & manufacturing at 2 renowned locations in North America:

A legacy of excellence in API/HPAPI capabilities and service:

30+ FDA Manufacturing Approvals (NCEs) including Multiple FDA Fast-Track APIs

More than $60M Invested in Recent Capacity Expansions

Frost & Sullivan Customer Value Leadership Award Winner

Winner for Compatibility, Quality, Reliability, & Service
CDMO LEADERSHIP AWARDS 2024

PATIENT CENTRICITY

Helping to reduce the burden of disease by prioritizing the needs of the patient.

TRUST

60+ years of successful experience with a strong complement of global regulatory approvals.

ONSHORING

Think global, act local. Onshore your APIs in North America.

Find out more here.

Piramal Pharma Solutions

Will 2024 Unlock Options **Enabling Our Technologies?**

LOUIS GARGUILO Chief Editor, *Outsourced Pharma* LouisGarguilo@LinkedIn

DOUG BAKAN
EVP, Technical Operations and Quality Assurance,
Ventyx Biosciences, Inc.

JOANNE TZOUVALOPOULOS BECK
Chief Technology Officer,
Aerium Therapeutics

DARREN DASBURG
CEO,
Clarus Biologics Inc.

JANA SPES
Principal Consultant,
JT Biopharma Partners

JOSEPH GRASKEMPER
Director, External Network Strategy,
Biogen

"I can speak from our experience with CDMOs throughout 2023 that the biggest challenge we face is still capacity, particularly for a number of technologies," says *Outsourced Pharma* Advisory Board member Doug Bakan, EVP, technical operations and quality assurance, Ventyx Biosciences, Inc.

Along with Bakan (who just left Ventyx as we were publishing this), a number of our board members offered what they saw as the speed bumps of 2023 and provided a few provocative questions on how to flatten them in 2024.

START WITH CAPACITY

Ventyx is a clinical-stage biopharma advancing oral therapies for patients living with autoimmune and inflammatory disorders, and it has an impressive pipeline including three drug candidates in Phase 2.

In the past 12 months, Bakan says, Ventyx has often been informed the "next available slot" at CDMOs for development or manufacturing needs remains from nine to 12 months out.

"For smaller companies on limited budgets, locking up capital to reserve slots so far in advance is challenging. Clinical development plans can change well ahead of the originally planned manufacturing date," Bakan says.

That in turn can lead to "steep cancellation penalties or — worse yet — huge delays to get the next slot, which can be yet another matter of months in some cases."

What should 2024 ring in?

In an ideal world, says Bakan, and one that should be manageable to both sponsors and service providers, "CDMOs would have capacity to slot in manufacturing campaigns with three to four months lead time at most. Anything our industry can do to make this a reality would be exceedingly helpful for innovator companies."

But for now, a suffocating challenge Bakan faced in 2023 is severely limited access to certain technologies at CDMOs.

An example is the manufacture of highly potent compounds, where there is at least some good news heading into 2024. "I think it is improving as more CDMOs upgrade facilities and personnel to handle those compounds," Bakan says.

On the other hand, spray drying is an example where the industry is still "woefully under-resourced," and Bakan fears there's some unfortunate market influences exacerbating the challenges.

"There are a couple of companies that have dominated that service sector for years," he says, "and in some cases they've implemented aggressive business practices to ensure competition doesn't impact their own business plans.

"I understand that can be good for their bottom line, but it's not so good for the many biopharma companies that need contract spray-drying services in an environment with limited options to begin with."

Here, too, there may be bright spots developing for 2024, as a number of service providers are in the process of adding new or additional spray-drying capabilities. Still, it appears those services coming online are already booked through the first six to nine months from the start-up of operations.

So while 2023 was a good year for Ventyx's pipeline and future overall, Bakan says it has proven frustrating navigating the CDMO space.

"Unless something changes in the industry to provide increased capacity and timely access to services," he says, "I'm not confident 2024 will be any easier for smaller companies needing to access specialized technologies at external partners."

TECH FOR TECH

Here are some of the questions I asked of our board members that elicited the discussion above:

"Considering science/technologies/platforms in 2024, will the focus be on oligonucleotides, vaccines, specific advancing cell/gene platforms, or the integration/utilization of AI/ML or other digital intelligences? Will it be broadly RNA considered — or has RNA, as they say, sucked the air out of the room, and now will it be put back among the other trending platforms?"

Joanne Tzouvalopoulos Beck, chief technology officer, Aerium Therapeutics, whose career has run through organizations such as Genentech, Amgen, AbbVie/Abbott, Shire, and Celgene, decided to answer with some questions of her own to help guide our readers:

- Regarding technology platforms, should we consider looking at what the common elements are and how they can be used to help us develop facilities, equipment, and workforces that can support several different modalities?
- Can we improve our utilization of AI to better predict and control the end-to-end supply chain by working together?

A third long-time board member, Jana Spes, principal consultant, JT Biopharma Partners, agrees with Beck that 2024 could be the year for "utilization of AI."

"Artificial intelligence is a great opportunity for our industry to reduce human errors," she says.

"I'd assign AI to work for us like a 'quality cop,' ensuring first that none of the repetitive, routine tasks still performed in our labs and factories contain errors.

"Then there are opportunities to automate review of batch records, calibration, maintenance, other quality tasks, and auto-generate repetitive document templates."

Joseph Graskemper, director, external network strategy, Biogen, directed his comments to the mRNA portion of my question.

"I certainly could be wrong," he says, "but I think mRNA had its moment as a COVID vaccine platform. Now there are a lot of questions around mRNA's application for therapeutics," which is exactly where the financial backers and developers of that technology are rushing toward.

More generally, Graskemper adds, "Advanced therapies had an enormous amount of growth in a short period of time."

That pace, he feels, is slowing down, "and normalizing against the current economic environment.

"Understanding that raising capital is currently difficult, it puts the advanced therapies industry in a bit of a conundrum. There's tremendous pressure on moving forward, patient accessibility, and the overall cost of these new therapies."

For 2024, Graskemper wonders:

"How can we expect innovators and CDMOs to improve R&D and manufacturing processes without the investment needed for process intensification and integration/utilization of technologies such as AI/ML? And can we learn to do better with less resources? Digitalization is now critical," he adds.

Finally, Darren Dasburg, CEO of Clarus Biologics Inc., and a board member I've often consulted on advancing technologies (he's a Big Pharma veteran, educator, and biotech entrepreneur), says more digitization and automation/robotics in our facilities "pushes us forward to the leanest manufacturing plants possible."

"This moves us to manufacturing profiles more like semiconductor fabs, or even EV-battery assembly operations, and helps us prepare for the lower number of STEM employees emanating from colleges."

Unfortunately, we still have not established general models for cost- or risk-sharing for the implementation of new technologies in our CDMOs that will enable the new technologies in our pipelines.

Perhaps 2024 will bring more of that.

Insights From The 13th Annual CDMO Leadership Awards

On Industry Trends And Variances In Customer Satisfaction

KATE HAMMEKE @ISRreports

The biopharmaceutical industry has experienced significant growth in the past two decades, and it is predicted to continue to grow, with some forecasts estimating a double-digit CAGR between 2022 and 2030.

With growth often come changes — new discoveries, new partnerships, and new companies formed through mergers and acquisitions, just to name a few. We have talked about how new relationship dynamics between sponsors and CDMOs have brought about new trends in outsourcing, both in the activities and services outsourced, and in the way CDMOs are viewed and valued by the innovator companies that depend on them to bring new medicines to market. Through the growth and industry changes, the goal of the CDMO Leadership Awards remains the same: to help simplify the complex and time-consuming process of selecting and qualifying a contract manufacturer.

This is the 13th year of Life Science Connect's annual *CDMO Leadership Awards*. The awards recognize contract development and manufacturing organizations that exceed customer expectations and stand out among the competition for their excellence. These awards are derived from feedback collected through four different quantitative surveys on contract manufacturing — biologic API, biologic drug product, small molecule API and small molecule drug product — conducted by Industry Standard Research (ISR), a full-service market research provider to the pharma and pharma services industries.

Potential participants are randomly selected from a database with over 5,000 drug innovator companies. Those who respond to the invitation are screened for decision-making influence and authority as well as their areas of expertise and the types of products they are responsible for outsourcing. Then they are directed to surveys that match their qualifications. The detailed information, by molecule type and manufacturing category, is available in ISR's suite of *CDMO Quality Benchmarking* reports. For the CDMO Leadership Awards, the service-specific data is aggregated to provide a company-wide score.

Five hundred thirty people involved in outsourced manufacturing participated in the research by providing their opinions of their experiences with the CDMOs that have supported their manufacturing needs. Among the participants were a collective 1,832 service interactions with 77 CDMOs. Participants in the research evaluate the CDMOs they have worked with in the past 18 months on 23 various performance metrics, making the CDMO Leadership Awards experience-based, which is important because it reflects how well a contract manufacturer delivers its services for its customers. Unlike perception-based data focused on a CDMO's reputation in the industry — a product of marketing and public relations spin — when making CDMO selection decisions, data on how well a manufacturer provided its services to its customers has real value in guiding an outsourcer to the right manufacturing partner.

ISR aggregates the individual CDMO performance data to establish the industry averages for each award category. Individual CDMO's scores are then compared to the industry average in each category, as well as in each respondent group breakout, large pharma (annual R&D is >$1 billion) and non-large pharma (annual R&D is <$1 billion), to identify the

winning CDMOs. There are six main award categories: Capabilities, Compatibility, Expertise, Quality, Reliability, and Service. Each award category is composed of four to six performance metrics.

IN WHICH CDMO LEADERSHIP AWARD CATEGORIES ARE CDMOs PERFORMING THE BEST?

An important and ongoing finding of note is that CDMOs consistently meet — or rather, exceed — the expectations of outsourcers. When analyzing the data, ISR uses a five-point Likert scale to measure performance relative to customer expectations and assigns a point value to each response on the scale (-3, -1, 0, 1, 3). The distribution across the scale is multiplied by the point values to get an overall score for the attribute, and the attribute scores are added and averaged to establish the winning scores for the award categories. Right in the center of the scale, represented by zero, is the "meets expectations" standing. An overall score above zero on any attribute relays that a CDMO exceeded the expectations of its customers. When a whole award category has an average score above zero, it means that the CDMO industry as a whole is meeting the expectations of sponsors across all of the attributes that compose the award category. Once again, the average scores in each of the award categories are above zero and highlight how CDMOs go beyond meeting expectations.

Consistent with 2020 (the last time we looked at the award categories in ranked order), the CDMO Leadership Award category where the industry average is highest is Service. When outsourcers were asked how the contract development and manufacturing organizations they have worked with in the past 18 months met their expectations, CDMOs received the highest average scores on their abilities to fulfill the services for which they were hired, involving Analytical services, including stability and storage testing, Preformulation/Formulation support, Process development and optimization, and Regulatory support. CDMOs received their second-highest average scores in the Expertise category, which includes the Ability to smoothly scale up manufacturing and transfer technology, Experience level of staff, Offers innovative solutions, Scientific knowledge, and Regulatory support.

Capabilities follows with the third-highest industry average among the six award categories. The Capabilities award category is a combination of All facilities fully owned, Complementary core competencies, Facility has the most up-to-date manufacturing technologies, Full range of manufacturing for the dosage forms we require, Has capacity to meet our demands, and Offers innovative solutions. Compatibility takes fourth position and includes Accessible senior management, Complementary core competencies, Timely project communications, and Well-regarded within the industry.

Reliability lands in fifth place this year. The award category includes All facilities fully owned, Has capacity to meet our demands, Reliable on-time delivery, Timely project communications, and Up-front contingency planning, risk management. The Quality award category has the lowest overall average, yet the average is still above the "meets expectations" mark. Some attributes in the Reliability category are also in the Quality category, like Up-front contingency planning, risk management, while Right first time measurements, Strong Regulatory track record, and Meeting quality performance metrics are unique to the Quality award.

In breaking out large pharma from non-large pharma, the data shows the award categories in the same ranked order as the overall data set for both groups, but what is thought-provoking is how much higher ratings from large pharma are compared to non-large pharma. In looking at the top-scoring category, Service, the average ratings offered by large pharma respondents are nearly double the average provided by non-large pharma. This is true for the Expertise and Capabilities categories as well — large pharma respondents' ratings are twice as high in aggregate than ratings from their non-large peers. Interestingly, the divide widens in categories that ranked lower. Large pharma ratings for Compatibility are nearly three times those of non-large pharma. The average Reliability ratings are over three times greater and the average Quality rating among large pharma is more than four times higher than the average among non-large pharma.

The question for CDMOs to ask is: Why are non-large pharma respondents less satisfied with their CDMOs' service delivery? Perhaps more importantly, what can CDMOs do to improve their relationships with non-large outsourcers?

KATE HAMMEKE, CEO,
Industry Standard Research

Survey Methodology: Industry Standard Research's Contract Manufacturing Quality Benchmarking research is conducted annually via online surveys. For the 2024 CMO Awards data, 77 contract manufacturers were evaluated on 23 different performance metrics. Research participants were recruited from biopharmaceutical companies of all sizes and screened for decision-making influence and authority when it comes to working with contract manufacturing suppliers. ***Respondents only evaluate companies with which they have worked on an outsourced project within the past 18 months.*** This level of qualification ensures that quality ratings come from actual involvement with a business and that companies identified as leaders are backed by experiential data.

Lists Of Winners
Page 16-23

Company Profiles
Page 24-33

CDMO LEADERSHIP AWARDS 2024

Outsourced Pharma and *Life Science Connect's* readership of pharmaceutical and biopharmaceutical executives have told us about their struggles in efficiently vetting potential CDMO partners. In response to this input, the CDMO Leadership Awards were developed.

Based on research from ISR Reports' Contract Manufacturing Quality Benchmarking annual online surveys, 98 contract manufacturers were evaluated on 23 different performance metrics. Research participants were recruited from biopharmaceutical companies of all sizes and were screened for decision-making influence and authority when it comes to working with contract manufacturing suppliers. Respondents only evaluated companies with which they have worked on an outsourced project in the past 18 months. This level of qualification ensures that quality ratings come from actual involvement with a business and that companies identified as leaders are backed by experiential data. CDMOs have an opportunity to win these awards in up to three groups of outsourcing respondents — Big Pharma, Small Pharma, and Overall (combined Big and Small Pharma).

WHAT ARE THE AWARDS?

ISR's survey participants were asked to provide an expectation rating for each CDMO they have worked with in the past 18 months in one of four outsourced manufacturing surveys — Small Molecule API, Biologic API, Small Molecule Drug Product, and Biologic Drug Product. Respondents answered questions on outsourcing practices and preferences and rated CDMOs across 23 performance attributes. Points were then totaled for a combined score for each attribute, and a composite score for each core category was determined. Winning CDMOs were identified when comparing their overall score vs. the competitive set.

We also recognize those companies that scored one standard deviation or more above the weighted average in each of the core categories. You will see these companies noted as the *Champions*.

To learn more about ISR's industry reports, customized research, or to be included in future CDMO Leadership Awards annual surveys, visit isrreports.com or contact ISR at (919) 301-0106.

PRESENTED BY:

OUTSOURCED PHARMA

LIFE SCIENCE CONNECT

RESEARCH CONDUCTED BY:

ISR reports

Smarter questions ∴ Smarter answers

INSIGHTS TO HELP YOU BETTER MEET YOUR ORGANIZATION'S NEEDS

Analyze the drug manufacturing environment, identify the best outsourcing models, and make smarter decisions based on hard data from outsourcing peers.

Recent reports include:

Major topics include:

- Biologics
- Bioprocessing
- Cell & Gene Therapies
- Small Molecules
- Sterile Injectables
- Oral Dosage Forms

(919) 301-0106 ISRreports.com info@ISRreports.com

ISR reports

CDMO LEADERSHIP AWARDS 2024 CAPABILITIES

- All facilities fully owned
- Complementary core competencies to in-house or other manufacturing contractors
- Facility has most up-to-date manufacturing technologies
- Full range of manufacturing for the dosage forms we require
- Has capacity to meet our demands
- Offers innovative solutions

CAPABILITIES

CHAMPIONS

OVERALL

IDT Biologika
Boehringer Ingelheim Biopharmaceuticals GmbH
Pfizer CentreOne
AbbVie

BIG PHARMA

Boehringer Ingelheim Biopharmaceuticals GmbH
GSK Contract Manufacturing
AbbVie

SMALL PHARMA

Boehringer Ingelheim Biopharmaceuticals GmbH
Bachem AG

EXCEEDED CUSTOMER EXPECTATIONS

OVERALL

WuXi Biologics
Bachem AG
GSK Contract Manufacturing
Sandoz
Resilience
Vetter Pharma International
ChemPartner
WuXi STA, a subsidiary of WuXi AppTec
Samsung Biologics
Lonza
FAMAR
CARBOGEN AMCIS
Ajinomoto Bio-Pharma Services
Simtra BioPharma Solutions
Thermo Fisher Scientific
FUJIFILM Diosynth Biotechnologies
Recipharm

BIG PHARMA

Pfizer CentreOne
Vetter Pharma International
Ajinomoto Bio-Pharma Services
WuXi Biologics
Samsung Biologics
FUJIFILM Diosynth Biotechnologies
Lonza
Thermo Fisher Scientific

SMALL PHARMA

Pfizer CentreOne
WuXi Biologics
KBI Biopharma, Inc.
AbbVie
WuXi STA, a subsidiary of WuXi AppTec
Almac Group
Lonza
Recipharm
Simtra BioPharma Solutions
Catalent
Vetter Pharma International
GSK Contract Manufacturing
Thermo Fisher Scientific

The terms "Small Pharma" and "Big Pharma" pertain to the outsourcing respondents, not the winners. "Overall" is a combination of Big and Small Pharma.
To be recognized as a Champion, company must have scored one standard deviation or more above the weighted average in the particular category respondent group.

CDMO LEADERSHIP AWARDS 2024 COMPATIBILITY

- Accessible senior management
- Complementary core competencies to in-house or other manufacturing contractors
- Timely project communications
- Well-regarded within the industry

COMPATIBILITY

CHAMPIONS

OVERALL

IDT Biologika
Boehringer Ingelheim Biopharmaceuticals GmbH
Resilience
Sandoz
Pfizer CentreOne

BIG PHARMA

Boehringer Ingelheim Biopharmaceuticals GmbH
GSK Contract Manufacturing
AbbVie

SMALL PHARMA

Boehringer Ingelheim Biopharmaceuticals GmbH
WuXi Biologics

EXCEEDED CUSTOMER EXPECTATIONS

OVERALL

AbbVie
WuXi Biologics
GSK Contract Manufacturing
Vetter Pharma International
Samsung Biologics
Simtra BioPharma Solutions
WuXi STA, a subsidiary of WuXi AppTec
CARBOGEN AMCIS
ChemPartner
Lonza
Thermo Fisher Scientific
Ajinomoto Bio-Pharma Services
Syngene International Ltd.
GenScript ProBio USA Inc
Piramal Pharma Solutions
Olon Group

BIG PHARMA

Vetter Pharma International
Pfizer CentreOne
Ajinomoto Bio-Pharma Services
Samsung Biologics
FUJIFILM Diosynth Biotechnologies
WuXi Biologics
Simtra BioPharma Solutions
Lonza
Thermo Fisher Scientific

SMALL PHARMA

Pfizer CentreOne
KBI Biopharma, Inc.
Simtra BioPharma Solutions
WuXi STA, a subsidiary of WuXi AppTec
AbbVie
Almac Group
Lonza
Vetter Pharma International
Piramal Pharma Solutions
Catalent
Recipharm
Thermo Fisher Scientific
MilliporeSigma

CDMO LEADERSHIP AWARDS 2024 EXPERTISE

- Ability to smoothly scale up manufacturing and transfer technology
- Experience level of staff
- Offers innovative solutions
- Regulatory support
- Scientific knowledge

EXPERTISE

CHAMPIONS

OVERALL

Boehringer Ingelheim Biopharmaceuticals GmbH
IDT Biologika
Pfizer CentreOne

BIG PHARMA

Boehringer Ingelheim Biopharmaceuticals GmbH
GSK Contract Manufacturing
AbbVie
Pfizer CentreOne

SMALL PHARMA

Boehringer Ingelheim Biopharmaceuticals GmbH
Bachem AG
Pfizer CentreOne

EXCEEDED CUSTOMER EXPECTATIONS

OVERALL

AbbVie
Resilience
Simtra BioPharma Solutions
Sandoz
Bachem AG
GSK Contract Manufacturing
FAMAR
WuXi Biologics
Vetter Pharma International
Samsung Biologics
ChemPartner
Ajinomoto Bio-Pharma Services
Lonza
Evotec
Grifols International, S.A.
WuXi STA, a subsidiary of WuXi AppTec
MilliporeSigma

BIG PHARMA

Ajinomoto Bio-Pharma Services
Vetter Pharma International
Simtra BioPharma Solutions
Samsung Biologics
WuXi Biologics
FUJIFILM Diosynth Biotechnologies
Lonza

SMALL PHARMA

KBI Biopharma, Inc.
Simtra BioPharma Solutions
WuXi Biologics
AbbVie
Lonza
Evotec
Vetter Pharma International
Recipharm
WuXi STA, a subsidiary of WuXi AppTec
GSK Contract Manufacturing
MilliporeSigma
Samsung Biologics
Almac Group
Thermo Fisher Scientific

The terms "Small Pharma" and "Big Pharma" pertain to the outsourcing respondents, not the winners. "Overall" is a combination of Big and Small Pharma.
To be recognized as a Champion, company must have scored one standard deviation or more above the weighted average in the particular category respondent group.

CDMO LEADERSHIP AWARDS 2024 QUALITY

- Right first time measurements
- Strong regulatory track record
- Track record for meeting quality performance metrics
- Up-front contingency planning, risk management

QUALITY

CHAMPIONS

OVERALL

IDT Biologika
Boehringer Ingelheim Biopharmaceuticals GmbH
Pfizer CentreOne
AbbVie

BIG PHARMA

AbbVie
GSK Contract Manufacturing

SMALL PHARMA

Boehringer Ingelheim Biopharmaceuticals GmbH
Pfizer CentreOne

EXCEEDED CUSTOMER EXPECTATIONS

OVERALL

ChemPartner
GSK Contract Manufacturing
Vetter Pharma International
Resilience
Simtra BioPharma Solutions
Sandoz
GenScript ProBio USA Inc
FAMAR
Ajinomoto Bio-Pharma Services
Lonza
Samsung Biologics
WuXi Biologics
Wockhardt
Evotec
KBI Biopharma, Inc.
CARBOGEN AMCIS
MilliporeSigma
Recipharm
Thermo Fisher Scientific
Grifols International, S.A.

BIG PHARMA

Pfizer CentreOne
Ajinomoto Bio-Pharma Services
Boehringer Ingelheim Biopharmaceuticals GmbH
Vetter Pharma International
Simtra BioPharma Solutions
Samsung Biologics
Lonza
FUJIFILM Diosynth Biotechnologies
MilliporeSigma
WuXi Biologics

SMALL PHARMA

KBI Biopharma, Inc.
Simtra BioPharma Solutions
Vetter Pharma International
Lonza
Evotec
AbbVie
Recipharm
WuXi Biologics
Almac Group
GSK Contract Manufacturing
WuXi STA, a subsidiary of WuXi AppTec
Piramal Pharma Solutions
Bachem AG
Thermo Fisher Scientific
MilliporeSigma
CordenPharma International
Fareva

CDMO LEADERSHIP AWARDS 2024 RELIABILITY

- All facilities fully owned
- Has capacity to meet our demands
- Reliable, on-time delivery
- Timely project management
- Up-front contingency planning, risk management

RELIABILITY

CHAMPIONS

OVERALL

IDT Biologika
Boehringer Ingelheim Biopharmaceuticals GmbH
Pfizer CentreOne
AbbVie

BIG PHARMA

AbbVie
GSK Contract Manufacturing

SMALL PHARMA

Boehringer Ingelheim Biopharmaceuticals GmbH
Pfizer CentreOne

EXCEEDED CUSTOMER EXPECTATIONS

OVERALL

Grifols International, S.A.
GSK Contract Manufacturing
WuXi Biologics
Vetter Pharma International
Simtra BioPharma Solutions
Resilience
Samsung Biologics
ChemPartner
CARBOGEN AMCIS
WuXi STA, a subsidiary of WuXi AppTec
Ajinomoto Bio-Pharma Services
Lonza
Sandoz
Recipharm
GenScript ProBio USA Inc
Piramal Pharma Solutions
Almac Group
CordenPharma International
Thermo Fisher Scientific
Syngene International Ltd.

BIG PHARMA

Pfizer CentreOne
Ajinomoto Bio-Pharma Services
Boehringer Ingelheim Biopharmaceuticals GmbH
FUJIFILM Diosynth Biotechnologies
Vetter Pharma International
Samsung Biologics
WuXi Biologics
Lonza
Simtra BioPharma Solutions

SMALL PHARMA

WuXi Biologics
KBI Biopharma, Inc.
Simtra BioPharma Solutions
WuXi STA, a subsidiary of WuXi AppTec
Recipharm
AbbVie
Vetter Pharma International
Almac Group
Piramal Pharma Solutions
Bachem AG
Lonza
Fareva
CordenPharma International
Thermo Fisher Scientific
GSK Contract Manufacturing

The terms "Small Pharma" and "Big Pharma" pertain to the outsourcing respondents, not the winners. "Overall" is a combination of Big and Small Pharma.
To be recognized as a Champion, company must have scored one standard deviation or more above the weighted average in the particular category respondent group.

CDMO LEADERSHIP AWARDS2024 SERVICE

- Analytical services, including stability and storage testing
- Drug substance/drug product manufacturing
- Preformulation/formulation support
- Process development and optimization
- Regulatory support

SERVICE

CHAMPIONS

OVERALL

ChemPartner
FAMAR
Sandoz
Boehringer Ingelheim Biopharmaceuticals GmbH
IDT Biologika
GSK Contract Manufacturing
Grifols International, S.A.

BIG PHARMA

Ajinomoto Bio-Pharma Services
GSK Contract Manufacturing

SMALL PHARMA

Boehringer Ingelheim Biopharmaceuticals GmbH
KBI Biopharma, Inc.
Pfizer CentreOne
Simtra BioPharma Solutions
GSK Contract Manufacturing
WuXi Biologics

EXCEEDED CUSTOMER EXPECTATIONS

OVERALL

Pfizer CentreOne
Ajinomoto Bio-Pharma Services
Resilience
WuXi Biologics
KBI Biopharma, Inc.
Vetter Pharma International
AbbVie
Simtra BioPharma Solutions
Wockhardt
Samsung Biologics
FUJIFILM Diosynth Biotechnologies
Lonza
Bachem AG
Recipharm
Piramal Pharma Solutions

BIG PHARMA

FUJIFILM Diosynth Biotechnologies
Vetter Pharma International
WuXi Biologics
Pfizer CentreOne
AbbVie
Boehringer Ingelheim Biopharmaceuticals GmbH
Piramal Pharma Solutions
Samsung Biologics
Simtra BioPharma Solutions

SMALL PHARMA

Bachem AG
Recipharm
Almac Group
Lonza
AbbVie
Vetter Pharma International
WuXi STA, a subsidiary of WuXi AppTec
Curia
CordenPharma International
Catalent
MilliporeSigma
Piramal Pharma Solutions

INDIVIDUAL ATTRIBUTE AWARDS

Outside of the core metrics of capabilities, compatibility, expertise, quality, reliability, and service, the Individual Attribute Awards identify common themes sponsor companies consider when choosing a supplier.

ACCESSIBLE SENIOR MANAGEMENT

TOP PERFORMERS

IDT Biologika
Resilience
Syngene International Ltd.

EXCEEDED CUSTOMER EXPECTATIONS

AbbVie
WuXi Biologics
Wockhardt
Piramal Pharma Solutions
Boehringer Ingelheim Biopharmaceuticals GmbH
Simtra BioPharma Solutions
WuXi STA, a subsidiary of WuXi AppTec
ChemPartner
Samsung Biologics
NextPharma
Pfizer CentreOne
CARBOGEN AMCIS
Rentschler
Bachem AG
Almac Group
GSK Contract Manufacturing
Thermo Fisher Scientific
Curia
FAMAR
Olon Group

INNOVATION

TOP PERFORMERS

Bachem AG
Boehringer Ingelheim Biopharmaceuticals GmbH
FAMAR
IDT Biologika
Pfizer CentreOne
Resilience

EXCEEDED CUSTOMER EXPECTATIONS

AbbVie
GenScript ProBio USA Inc
ChemPartner
Vetter Pharma International
GSK Contract Manufacturing
Syngene International Ltd.
Ajinomoto Bio-Pharma Services
WuXi Biologics
Samsung Biologics
Lonza
KBI Biopharma, Inc.
WuXi STA, a subsidiary of WuXi AppTec
FUJIFILM Diosynth Biotechnologies
Sandoz
Abzena
Evotec
Thermo Fisher Scientific
MilliporeSigma

ON-TIME DELIVERY

TOP PERFORMERS

IDT Biologika
Grifols International, S.A.
Boehringer Ingelheim Biopharmaceuticals GmbH

EXCEEDED CUSTOMER EXPECTATIONS

Simtra BioPharma Solutions
AbbVie
Pfizer CentreOne
GSK Contract Manufacturing
WuXi Biologics
Samsung Biologics
Olon Group
FAMAR
Evotec
Syngene International Ltd.
Vetter Pharma International
KBI Biopharma, Inc.
WuXi STA, a subsidiary of WuXi AppTec
GenScript ProBio USA Inc
CARBOGEN AMCIS
Ajinomoto Bio-Pharma Services
Recipharm
Piramal Pharma Solutions
Bachem AG
CordenPharma International
Fareva
Lonza
Wockhardt
Almac Group
Resilience

REPUTATION

TOP PERFORMERS

Boehringer Ingelheim Biopharmaceuticals GmbH
Sandoz
IDT Biologika
Vetter Pharma International
Pfizer CentreOne
ChemPartner

EXCEEDED CUSTOMER EXPECTATIONS

Simtra BioPharma Solutions
GSK Contract Manufacturing
AbbVie
Resilience
Samsung Biologics
Lonza
GenScript ProBio USA Inc
WuXi Biologics
Thermo Fisher Scientific
WuXi STA, a subsidiary of WuXi AppTec
Bachem AG

INDIVIDUAL ATTRIBUTE AWARDS

RIGHT FIRST TIME

TOP PERFORMERS

IDT Biologika
GSK Contract Manufacturing
Boehringer Ingelheim Biopharmaceuticals GmbH

EXCEEDED CUSTOMER EXPECTATIONS

FAMAR
AbbVie
Resilience
Vetter Pharma International
ChemPartner
Pfizer CentreOne
GenScript ProBio USA Inc
CARBOGEN AMCIS
Lonza
Ajinomoto Bio-Pharma Services
Recipharm
Samsung Biologics
Simtra BioPharma Solutions
KBI Biopharma, Inc.
Evotec
WuXi Biologics
MilliporeSigma
Sandoz

STATE-OF-THE-ART

TOP PERFORMERS

Boehringer Ingelheim Biopharmaceuticals GmbH
Sandoz

EXCEEDED CUSTOMER EXPECTATIONS

IDT Biologika
WuXi Biologics
AbbVie
Pfizer CentreOne
Resilience
GSK Contract Manufacturing
Bachem AG
Vetter Pharma International
Samsung Biologics
Lonza
Olon Group
FUJIFILM Diosynth Biotechnologies
Recipharm
WuXi STA, a subsidiary of WuXi AppTec
CARBOGEN AMCIS
Simtra BioPharma Solutions
KBI Biopharma, Inc.
Thermo Fisher Scientific

STRENGTH OF SCIENCE

TOP PERFORMERS

Boehringer Ingelheim Biopharmaceuticals GmbH
Sandoz
Pfizer CentreOne
Simtra BioPharma Solutions
Wockhardt

EXCEEDED CUSTOMER EXPECTATIONS

AbbVie
Resilience
FAMAR
IDT Biologika
Vetter Pharma International
GenScript ProBio USA Inc
Samsung Biologics
Bachem AG
GSK Contract Manufacturing
WuXi Biologics
WuXi STA, a subsidiary of WuXi AppTec
Lonza
KBI Biopharma, Inc.

CATEGORIES WON:

AbbVie

North Chicago, IL

abbviecontractmfg.com

Phone: 847-938-8524

Contact: Jeff Tremain

Email: jeffrey.tremain@abbvie.com

KEY LOCATIONS: USA (3 sites), Puerto Rico (2 sites), Germany (1 site), Italy (1 site), Ireland (5 sites)

DRUG TYPE:
Biopharmaceuticals, Pharmaceuticals

DRUG LIFE CYCLE STAGES:
Research & Development: Clinical (Phase 1, Phase 2, Phase 3)

Drug Substance Production: Drug Substance Production

Formulated Drug Production: Dosage Form Production, Packaging

SERVICES & CAPABILITIES: AbbVie contract manufacturing offers the following services: Aseptic Fill/Finish, Biologics, Custom API, High Potent API, Eye Care, Hot Melt Extrusion, Microbial Fermentation, Oral Solid Dose, Topical, Antibody Drug Conjugates.

INDIVIDUAL ATTRIBUTE AWARDS: Accessible Senior Management, Innovation, On-Time Delivery, Right First Time, State-of-the-Art, Strength of Science

CATEGORIES WON:

Ajinomoto Bio-Pharma Services

San Diego, CA

AjiBio-Pharma.com

Contact: Jenn Etchison

Email: jennifer.etchison@us.ajibio-pharma.com

KEY LOCATIONS: USA, Belgium, Japan, India

DRUG TYPE:
Biopharmaceuticals, Pharmaceuticals

DRUG LIFE CYCLE STAGES:
Research & Development: Discovery, Preclinical, Clinical (Phase 1, Phase 2, Phase 3)

Drug Substance Production: Primary Process Development, Drug Substance Production

Formulated Drug Production: Dosage Form Development, Packaging, Logistics

SERVICES & CAPABILITIES: We provide comprehensive process development services, cGMP manufacturing and drug product fill/finish services of small molecule and large molecule APIs and intermediates. We're dedicated to providing a high level of quality and can support projects from preclinical through commercial production.

INDIVIDUAL ATTRIBUTE AWARDS:
Innovation, On-Time Delivery, Right First Time

CATEGORIES WON:

Almac Group

Craigavon, Northern Ireland, UK

almacgroup.com

Email: info@almacgroup.com

KEY LOCATIONS: Craigavon, UK; Charnwood, UK; Athlone, Ireland; Audubon, PA, USA

DRUG TYPE:
Biopharmaceuticals, Pharmaceuticals

DRUG LIFE CYCLE STAGES:
Research & Development: Preclinical, Clinical (Phase 1, Phase 2, Phase 3)

Drug Substance Production: Primary Process Development, Drug Substance Production

Formulated Drug Production: Dosage Form Development, Dosage Form Production, Packaging, Logistics

SERVICES & CAPABILITIES: Addressing the growing need to develop and manufacture clinical candidates faster, Almac provides a fully integrated CMC solution, bridging the gap between drug substance and drug product development from a single source assuring scientific continuity and savings in time and costs.

INDIVIDUAL ATTRIBUTE AWARDS: Accessible Senior Management, On-Time Delivery

CATEGORIES WON:

Bachem AG

Bubendorf, Basel-Landschaft, Switzerland

bachem.com

Phone: +4158 595 20 21

Contact: Boris Corpataux

Email: boris.corpataux@bachem.com

KEY LOCATIONS: Bubendorf, Basel-Landschaft, Switzerland; Vionnaz, Valais, Switzerland; St. Helens, England, UK; Torrance, CA, USA; Vista, CA, USA

DRUG TYPE:
Pharmaceuticals

DRUG LIFE CYCLE STAGES:
Research & Development: Preclinical, Clinical (Phase 1, Phase 2, Phase 3)

Drug Substance Production: Primary Process Development, Drug Substance Production

SERVICES & CAPABILITIES:
Bachem offers a full range of CMC services in the manufacturing of peptides and oligonucleotides for clinical and commercial APIs. We support our clients from R&D scale process transfer or process development to scale-up, GMP production, clinical trials, and commercial release.

INDIVIDUAL ATTRIBUTE AWARDS: Accessible Senior Management, Innovation, On-Time Delivery, Reputation, State-of-the-Art, Strength of Science

CATEGORIES WON:

Boehringer Ingelheim Biopharmaceuticals GmbH

Ingelheim, Germany

bioxcellence.com

Phone: +49 6132 770

Email: bioxcellence@boehringer-ingelheim.com

KEY LOCATIONS: Biberach, Germany; Vienna, Austria; Fremont, CA, USA; Shanghai, China

DRUG TYPE:
Biopharmaceuticals

DRUG LIFE CYCLE STAGES:
Research & Development: Clinical (Phase 1, Phase 2, Phase 3)

Drug Substance Production: Drug Substance Production

Formulated Drug Production: Dosage Form Production

SERVICES & CAPABILITIES: Mammalian Cell Cultures - Manufacturing of various molecule formats from cell culture like monoclonal antibodies, antibody fragments, Fc fusions, and other recombinant proteins.

Microbial Technologies - Manufacturing of Fab fragment, peptide hormones, plasmid DNA, scaffolds, recombinant proteins, enzymes, and recombinant vaccines.

INDIVIDUAL ATTRIBUTE AWARDS: Accessible Senior Management, Innovation, On-Time Delivery, Reputation, Right First Time, State-of-the-Art, Strength of Science

CATEGORIES WON:

CARBOGEN AMCIS

Bubendorf, Switzerland

carbogen-amcis.com

Contact: Estelle Vassy

Email: estelle.vassy@carbogen-amcis.com

KEY LOCATIONS: Saint-Beauzire, France; Manchester, UK; Shanghai, China; Bubendorf, Switzerland; Neuland, Switzerland; Vionnaz, Switzerland

DRUG TYPE:
Biopharmaceuticals, Pharmaceuticals

DRUG LIFE CYCLE STAGES:
Research & Development: Preclinical, Clinical (Phase 1, Phase 2, Phase 3)

Drug Substance Production: Primary Process Development, Drug Substance Production

Formulated Drug Production: Dosage Form Development, Dosage Form Production, Logistics

SERVICES & CAPABILITIES: CARBOGEN AMCIS is a leading service provider CDMO, offering a portfolio of drug development and commercialization services to the pharmaceutical and biopharmaceutical industries at all stages of drug development. Drug Substances and Drug Products services and supply.

INDIVIDUAL ATTRIBUTE AWARDS: Accessible Senior Management, On-Time Delivery, Right First Time, State-of-the-Art

CATEGORIES WON:

Catalent

Somerset, NJ

catalent.com

Phone: US: +1 877-587-1835
EU/ROW: 00800 88 55 6178

Contact: Sherief Shaaban

Email: Sherief.shaaban@catalent.com

KEY LOCATIONS: Catalent has more than 50 locations worldwide, including: St. Petersburg, FL, USA; Bloomington, IN, USA; Greendale, IN, USA; Harmans/BWI, MD, USA; Winchester, KY, USA; Gosselies, Belgium

DRUG TYPE:
Biopharmaceuticals, Pharmaceuticals

DRUG LIFE CYCLE STAGES:
Research & Development: Preclinical, Clinical (Phase 1, Phase 2, Phase 3)

Drug Substance Production: Primary Process Development, Drug Substance Production

Formulated Drug Production: Dosage Form Development, Dosage Form Production, Packaging, Logistics

SERVICES & CAPABILITIES: Catalent provides differentiated development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, vaccines, and consumer health products at over 50 facilities across four continents under rigorous quality and operational standards.

CATEGORIES WON:

CordenPharma International

Basel, Switzerland

cordenpharma.com

Phone: 303-442-1926

Contact: Mimoun Ayoub

Email: salesforce@cordenpharma.com

KEY LOCATIONS: Boulder, CO, USA; Bergamo, Italy; Caponago, Italy; Plankstadt, Germany; Liestal, Switzerland; Fribourg, Switzerland

DRUG TYPE:
Pharmaceuticals

DRUG LIFE CYCLE STAGES:
Research & Development: Preclinical, Clinical (Phase 1, Phase 2, Phase 3)

Drug Substance Production: Primary Process Development, Drug Substance Production

Formulated Drug Production: Dosage Form Development, Dosage Form Production, Packaging

SERVICES & CAPABILITIES: cGMP Development & Manufacturing of Peptides, Oligonucleotides, custom & standard Lipid Excipients, Lipid NanoParticles (LNPs), sterile Injectables, and the extensive supply of Small Molecules (both Highly Potent & Regular Potency) covering clinical to commercial supply.

INDIVIDUAL ATTRIBUTE AWARDS: On-Time Delivery

CATEGORY WON:

Curia

Albany, NY

curiaglobal.com

Phone: +1 518-512-2000

Contact: Christopher Conway

Email: Christopher.Conway@curiaglobal.com

KEY LOCATIONS: Rensselaer, NY, USA; Albuquerque, NM, USA; Valladolid, Spain; Origgio, Italy; Bon-Encontre, France; Aurangabad, India

DRUG TYPE:
Biopharmaceuticals, Pharmaceuticals

DRUG LIFE CYCLE STAGES:
Research & Development: Discovery, Preclinical, Clinical (Phase 1, Phase 2, Phase 3)

Drug Substance Production: Primary Process Development, Drug Substance Production

Formulated Drug Production: Dosage Form Development, Dosage Form Production, Logistics

SERVICES & CAPABILITIES: Curia provides comprehensive small molecule services, from IND to commercialization, including APIs, steroids, hormones, HPAPIs, lipid nanoparticles and fine chemicals. Our biologics offering spans discovery to clinic, featuring mRNA, mAb, proteins, vaccines, cell lines, viral vectors, peptides, and oligonucleotides.

INDIVIDUAL ATTRIBUTE AWARDS: Accessible Senior Management

CATEGORIES WON:

Evotec

Hamburg, Germany

evotec.com

Phone: +49.(0)40.5 60 81-0

Contact: Christian Buhlmann

Email: christian.buhlmann@evotec.com

KEY LOCATIONS: Verona and Modena, Italy; Halle, Germany; Abingdon, Oxfordshire, UK; Toulouse, France; Seattle, WA, USA

DRUG TYPE:
Biopharmaceuticals, Pharmaceuticals

DRUG LIFE CYCLE STAGES:
Research & Development: Discovery, Preclinical, Clinical (Phase 1, Phase 2, Phase 3)

Drug Substance Production: Primary Process Development, Drug Substance Production

Formulated Drug Production: Dosage Form Development, Dosage Form Production

SERVICES & CAPABILITIES: Small molecules: drug substance and drug product development and GMP manufacturing from FIH to Phase 3; Custom manufacturing of cGMP intermediates; Biologics: J.POD® economical, small-footprint, deployable cGMP biomanufacturing from early development to commercial-scale quantities; cell and gene therapy manufacturing.

INDIVIDUAL ATTRIBUTE AWARDS: Innovation, On-Time Delivery, Right First Time

CATEGORIES WON:

FAMAR

Alimos, Athens, Greece

famar-group.com

Email: m.rotas@famar-group.com

KEY LOCATIONS: Baranzate, Milan, Italy; Alcorcon, Madrid, Spain; Alimos, Athens, Greece; Anthoussa, Greece; Avlonas 48, Avlonas, Greece; Avlonas 49, Avlonas, Greece

DRUG TYPE:
Pharmaceuticals

DRUG LIFE CYCLE STAGES:
Research & Development: Preclinical, Clinical (Phase 1, Phase 2, Phase 3)

Formulated Drug Production: Dosage Form Development, Dosage Form Production, Packaging, Logistics

SERVICES & CAPABILITIES: Development Services: From drug substance sourcing to the compilation and writing of dossiers in eCTD. Pharmaceutical Production Services: Solid, Sterile, Liquids and Semisolids, Consumer Care and Cosmetic Products and Secondary Packaging. Distribution and Logistics.

INDIVIDUAL ATTRIBUTE AWARDS: Accessible Senior Management, Innovation, On-Time Delivery, Right First Time, Strength of Science

CATEGORIES WON:

Fareva

Luxembourg

fareva.com

Phone: +4916090545489

Contact: Christian Miksch

Email: cmiksch.excella@fareva.com

KEY LOCATIONS: Feucht, Germany; Richmond, VA, USA; Riom, France; Val-de-Reuil, France; Unterach, Austria; Villa Rica, Colombia

DRUG TYPE:
Biopharmaceuticals, Pharmaceuticals

DRUG LIFE CYCLE STAGES:
Research & Development: Clinical (Phase 1, Phase 2, Phase 3)

Drug Substance Production: Primary Process Development, Drug Substance Production

Formulated Drug Production: Dosage Form Development, Dosage Form Production, Packaging

SERVICES & CAPABILITIES: We have industry-leading capabilities in development and manufacturing of a large range of Drug Products and APIs.

Fareva supports a broad range of therapeutic areas including vaccines, oncology, antibiotics, biologics, OTC, animal health and ophthalmic products. We are able to support our customers from early clinical phase programs, requiring small scale manufacturing, process optimization and scale-up, to launch and commercial phases.

All sites are state-of-the-art cGMP and accredited by several international pharmaceutical agencies such as the FDA, ANVISA, Russia, Japan, China, and others.

INDIVIDUAL ATTRIBUTE AWARDS: On-Time Delivery

CATEGORIES WON:

FUJIFILM Diosynth Biotechnologies

Research Triangle Park, NC

fujifilmdiosynth.com

Phone: 919-337-4400

Email: contactfdb@fujifilm.com

KEY LOCATIONS: Research Triangle Park, NC, USA; College Station, TX, USA; Teesside, UK; Hillerod, DK; Watertown, MA, USA; Thousand Oaks, CA, USA

DRUG TYPE:
Biopharmaceuticals

DRUG LIFE CYCLE STAGES:
Research & Development: Preclinical, Clinical (Phase 1, Phase 2, Phase 3)

Drug Substance Production: Primary Process Development, Drug Substance Production

Formulated Drug Production: Packaging

SERVICES & CAPABILITIES: FUJIFILM Diosynth Biotechnologies is an industry-leading cGMP Contract Development and Manufacturing Organization (CDMO) supporting the biopharmaceutical industry in the development and production of biologics, vaccines, and advanced therapies.

INDIVIDUAL ATTRIBUTE AWARDS: Innovation, State-of-the-Art

CATEGORIES WON:

GenScript ProBio USA Inc

Piscataway, NJ

genscriptprobio.com

Contact: Mark Thompson

Email: Mark.Thompson@genscriptprobio.com

KEY LOCATIONS: New Jersey, USA; Nanjing, China; Zhenjiang, China

DRUG TYPE:
Biopharmaceuticals, Pharmaceuticals

DRUG LIFE CYCLE STAGES:
Research & Development: Discovery, Preclinical, Clinical (Phase 1, Phase 2, Phase 3)

Drug Substance Production: Primary Process Development, Drug Substance Production

Formulated Drug Production: Dosage Form Development, Dosage Form Production

SERVICES & CAPABILITIES: We are a global CDMO accelerating manufacturing of life-changing drugs, discovering novel therapeutic targets, and developing innovative approaches to manufacture best-in-class RNA, DNA, and protein. As a manufacturing partner to pharmaceutical and biotech organizations, GenScript ProBio helps accelerate development of life-changing drugs, bringing expertise for advanced therapies manufacturing, including biologics, vaccines, cell and gene therapies, and antibody protein drugs, to realize the potential of your breakthrough discovery.

INDIVIDUAL ATTRIBUTE AWARDS: Innovation, On-Time Delivery, Reputation, Right First Time, Strength of Science

CATEGORIES WON:

Grifols International, S.A.

Sant Cugat del Valles, Barcelona, Spain

partnership.grifols.com

Phone: +34 93 571 2199

Contact: Marga Viñes

Email: marga.vines@grifols.com

KEY LOCATIONS: Parets del Vallès, Barcelona, Spain; Grange Castle, Dublin, Ireland

DRUG TYPE:
Pharmaceuticals

DRUG LIFE CYCLE STAGES:
Formulated Drug Production: Dosage Form Production

SERVICES & CAPABILITIES: Drug product development and technology transfer, Small molecule drug product manufacturing, Terminal sterilization, Light and O2 sensitive products, Glass vials (2,5 to 50 mL), Diluents - WFI, Glass bottles (50 to 500 mL), Flexible containers (PP bags, 50 to 1,000 mL), FFS technology for PP bags, Regulatory approvals.

INDIVIDUAL ATTRIBUTE AWARDS: On-Time Delivery

CATEGORIES WON:

IDT Biologika

Dessau-Rosslau, Saxony-Anhalt, Germany

idt-biologika.com

Phone: +49 34901 8850

Contact: Lifeng He

Email: lifeng.he@idt-biologika.com

KEY LOCATIONS: Dessau-Rosslau, Saxony-Anhalt, Germany; Rockville, MD, USA; Magdeburg, Saxony-Anhalt, Germany

DRUG TYPE:
Biopharmaceuticals, Pharmaceuticals

DRUG LIFE CYCLE STAGES:
Research & Development: Preclinical, Clinical (Phase 1, Phase 2, Phase 3)

Drug Substance Production: Primary Process Development, Drug Substance Production

Formulated Drug Production: Dosage Form Development, Dosage Form Production, Packaging

SERVICES & CAPABILITIES: End-to-end services in contract development and GMP manufacturing of vaccines, cell and gene therapeutics, fill/finish of sterile injectables, at clinical and commercial scale. Process development, drug substance, aseptic fill/finish, packaging, quality control, and analytics.

INDIVIDUAL ATTRIBUTE AWARDS: Accessible Senior Management, Innovation, On-Time Delivery, Reputation, Right First Time, State-of-the-Art, Strength of Science

CATEGORIES WON:

KBI Biopharma, Inc.

Durham, NC

kbibiopharma.com

Phone: 984-884-5407

Contact: Michael Cavanaugh

Email: mcavanaugh@kbibiopharma.com

KEY LOCATIONS: Durham, NC, USA; Boulder, CO, USA; Geneva, Switzerland

DRUG TYPE:
Biopharmaceuticals

DRUG LIFE CYCLE STAGES:
Research & Development: Preclinical, Clinical (Phase 1, Phase 2, Phase 3)

Drug Substance Production: Primary Process Development, Drug Substance Production

Formulated Drug Production: Dosage Form Development, Dosage Form Production

SERVICES & CAPABILITIES: Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI Biopharma, Inc., delivers process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs.

INDIVIDUAL ATTRIBUTE AWARDS: Innovation, On-Time Delivery, Right First Time, State-of-the-Art, Strength of Science

CATEGORIES WON:

MilliporeSigma

Burlington, MA

SigmaAldrich.com/MilliporeCTDMOServices

Contact: Zerina Spahic

Email: zerina.spahic@milliporesigma.com

KEY LOCATIONS: Europe: Martillac, France; Darmstadt, Hamburg Germany; Schaffhausen, Switzerland; Glasgow, Stirling, Scotland
USA: Burlington, MA; Carlsbad, CA; Madison and Verona, WI; Indianapolis, IN; Rockville, MD
Asia: Shanghai, China; Singapore

DRUG TYPE:
Biopharmaceuticals, Pharmaceuticals

DRUG LIFE CYCLE STAGES:
Research & Development: Preclinical, Clinical (Phase 1, Phase 2, Phase 3)

Drug Substance Production: Primary Process Development, Drug Substance Production

Formulated Drug Production: Logistics

SERVICES & CAPABILITIES: Our expert integrated Millipore® CTDMO Services focus on the highest patient-impact modalities: mAbs, viral vectors, ADC and bioconjugation, high potency APIs, and mRNA and LNP formulation. Designed to support all client needs, we provide a streamlined experience from preclinical to commercial.

INDIVIDUAL ATTRIBUTE AWARDS: Innovation, Right First Time

CATEGORY WON:

Olon Group

Milan, Italy

olonspa.com

Phone: +393386674289

Contact: Olon Spa

Email: sspina@olonspa.it

KEY LOCATION: Milan, Italy

DRUG TYPE:
Biopharmaceuticals, Pharmaceuticals

DRUG LIFE CYCLE STAGES:
Research & Development: Discovery

Drug Substance Production: Drug Substance Production

Formulated Drug Production: Dosage Form Development, Dosage Form Production

SERVICES & CAPABILITIES: Olon can be considered a real one-stop shop supporting all the phases of the development of a new drug starting from preclinical material up to the product required for the launch and commercial. In addition, we represent a one-stop shop from an operational standpoint since we can be involved in the production of an API starting from basic raw materials through regulatory starting materials, GMP-intermediates to the final API.

INDIVIDUAL ATTRIBUTE AWARDS: Accessible Senior Management, On-Time Delivery, State-of-the-Art

CATEGORIES WON:

Pfizer CentreOne

New York, NY

pfizercentreone.com

Contact: Tom Wilson

Email: tom.p.wilson@pfizer.com

KEY LOCATIONS: McPherson, KS, USA; Kalamazoo, MI, USA; Sanford, NC, USA; Ascoli Piceno, Italy; Puurs, Belgium; Newbridge, Ireland

DRUG TYPE:
Biopharmaceuticals

DRUG LIFE CYCLE STAGES:
Drug Substance Production: Primary Process Development, Drug Substance Production

Formulated Drug Production: Dosage Form Development, Dosage Form Production, Packaging, Logistics

SERVICES & CAPABILITIES: We leverage Pfizer's cutting-edge development and commercial manufacturing solutions to offer contract development and manufacturing services from small to large scale for oral solids, sterile injectables, small molecules and biologics, as well as regulatory services.

INDIVIDUAL ATTRIBUTE AWARDS: Accessible Senior Management, Innovation, On-Time Delivery, Reputation, Right First Time, State-of-the-Art, Strength of Science

CATEGORIES WON:

Piramal Pharma Solutions

Mumbai, Maharashtra, India

piramalpharmasolutions.com

Phone: +12035500125

Contact: Stuart Needleman

Email: Stuart.Needleman@piramal.com

KEY LOCATIONS: Riverview, MI, USA; Sellersville, PA, USA; Lexington, KY, USA; Grangemouth, UK; Morpeth, UK; Digwal, India

DRUG TYPE:
Pharmaceuticals

DRUG LIFE CYCLE STAGES:
Research & Development: Discovery, Preclinical, Clinical (Phase 1, Phase 2, Phase 3)

Drug Substance Production: Drug Substance Production

Formulated Drug Production: Dosage Form Development, Dosage Form Production

SERVICES & CAPABILITIES: Piramal Pharma Solutions (PPS) is a contract development and manufacturing organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia.

INDIVIDUAL ATTRIBUTE AWARDS: Accessible Senior Management, On-Time Delivery

CATEGORIES WON:

Recipharm

Stockholm, Sweden

recipharm.com

Email: info@recipharm.com

KEY LOCATIONS: Kaysersberg, France; Monheim/Zwickau, Germany; Wasserburg, Germany; Leganés, Spain; Lisbon, Portugal; Watertown, MA, USA

DRUG TYPE:
Biopharmaceuticals, Pharmaceuticals

DRUG LIFE CYCLE STAGES:
Research & Development: Preclinical, Clinical (Phase 1, Phase 2, Phase 3)

Drug Substance Production: Drug Substance Production

Formulated Drug Production: Dosage Form Development, Dosage Form Production, Packaging

SERVICES & CAPABILITIES: Recipharm manufactures pharmaceuticals and biologics in various dosage forms for customers ranging from Big Pharma to smaller R&D companies. We operate development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK, and the USA.

INDIVIDUAL ATTRIBUTE AWARDS: On-Time Delivery, Right First Time, State-of-the-Art

CATEGORIES WON:

Resilience

San Diego, CA

resilience.com

Contact: Holly He

Email: holly.he@resilience.com

KEY LOCATIONS: Boston, MA, USA; Alachua, FL, USA; Toronto, ON, Canada; Cincinnati, OH, USA; Philadelphia, PA, USA; Durham, NC, USA

DRUG TYPE:
Biopharmaceuticals

DRUG LIFE CYCLE STAGES:
Research & Development: Discovery, Preclinical, Clinical (Phase 1, Phase 2, Phase 3)

Drug Substance Production: Primary Process Development, Drug Substance Production

Formulated Drug Production: Dosage Form Development, Dosage Form Production, Logistics

SERVICES & CAPABILITIES: Resilience is a technology-focused biomanufacturing company dedicated to broadening access to complex medicines (biologics, vaccines, nucleic acid, cell/gene therapy modalities, and drug product). Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the treatments of today and tomorrow can be made quickly, safely, and at scale. By continuously advancing the science of biopharmaceutical manufacturing and development, Resilience seeks to free its partners to focus on the discoveries that improve patients' lives and protect biopharmaceutical supply chains against future disruptions.

INDIVIDUAL ATTRIBUTE AWARDS: Accessible Senior Management, Innovation, On-Time Delivery, Reputation, Right First Time, State-of-the-Art, Strength of Science

CATEGORIES WON:

Samsung Biologics

Yeonsu-gu, Incheon, South Korea

samsungbiologics.com

Phone: (82)324553114

Contact: Kevin Sharp

Email: sbio.bd@samsung.com

KEY LOCATIONS: Incheon, South Korea; San Francisco, CA, USA; Ridgefield Park, NJ, USA; Boston, MA, USA

DRUG TYPE:
Biopharmaceuticals

DRUG LIFE CYCLE STAGES:
Research & Development: Discovery, Preclinical, Clinical (Phase 1, Phase 2, Phase 3)

Drug Substance Production: Primary Process Development, Drug Substance Production

Formulated Drug Production: Dosage Form Development, Dosage Form Production, Packaging, Logistics

SERVICES & CAPABILITIES: Cell line development, Process development, Non-GMP/cGMP DS/DP production, DS & DP production, Aseptic Fill/Finish, Lyophilization, Stability/Biosafety/Analytical Testing, mRNA DS/DP production, ADC, Multimodality, Controlled Substances, Liquids, Proteins, Sterile

INDIVIDUAL ATTRIBUTE AWARDS: Accessible Senior Management, Innovation, On-Time Delivery, Reputation, Right First Time, State-of-the-Art, Strength of Science

Simtra BioPharma Solutions

CATEGORIES WON:

Simtra BioPharma Solutions

Parsippany, NJ

simtrabps.com

Contact: Bo Watkins

Email: bo_watkins@baxter.com

KEY LOCATIONS: Bloomington, IN, USA; Halle/Westfalen, Germany

DRUG TYPE:
Biopharmaceuticals, Pharmaceuticals

DRUG LIFE CYCLE STAGES:
Research & Development: Preclinical, Clinical (Phase 1, Phase 2, Phase 3)

Drug Substance Production: Primary Process Development, Drug Substance Production

Formulated Drug Production: Dosage Form Development, Dosage Form Production

SERVICES & CAPABILITIES: As a premier, independently owned CDMO with over 65 years of sterile injectable manufacturing experience, Simtra BioPharma Solutions offers world-class cGMP sterile fill/finish, technical expertise, quality service, and a uniquely collaborative approach. Pharmaceutical and biotech companies partner with Simtra when they face formulation challenges, clinical supply hurdles, surges in demand due to market fluctuations, or risk mitigation concerns. Our delivery systems include prefilled syringes, liquid/lyophilized vials, and diluents for reconstitution. Simtra can accommodate a variety of manufacturing requirements for an extensive selection of product types.

INDIVIDUAL ATTRIBUTE AWARDS: Accessible Senior Management, On-Time Delivery, Reputation, Right First Time, State-of-the-Art, Strength of Science

Syngene
Putting Science to Work

CATEGORIES WON:

Syngene International Ltd.

Bangalore, Karnataka, India

syngeneintl.com

Phone: +91-9035415639

Email: bdc@syngeneintl.com

KEY LOCATIONS: Bangalore, Karnataka, India; Mangalore, Karnataka, India

DRUG TYPE:
Biopharmaceuticals, Pharmaceuticals

DRUG LIFE CYCLE STAGES:
Research & Development: Discovery, Preclinical, Clinical (Phase 1, Phase 2, Phase 3)

Drug Substance Production: Primary Process Development, Drug Substance Production

Formulated Drug Production: Dosage Form Development, Dosage Form Production

SERVICES & CAPABILITIES: We offer integrated and end-to-end services across drug discovery, development, and commercial manufacturing for small molecules, and biologics, and specialty modalities such as peptides, oligonucleotides, ADCs, and targeted degradation/stabilization.

INDIVIDUAL ATTRIBUTE AWARDS: Accessible Senior Management, Innovation, On-Time Delivery

ThermoFisher SCIENTIFIC

CATEGORIES WON:

Thermo Fisher Scientific

Waltham, MA

patheon.com

Phone: 781-622-1045

Contact: Pharma Services Business Development

Email: pharmaservices@thermofisher.com

KEY LOCATIONS: Monza & Ferentino, Italy; Greenville, NC, USA; Singapore; Bourgoin, France; Whitby & Toronto, Canada; Cincinnati, OH, USA

DRUG TYPE:
Biopharmaceuticals, Pharmaceuticals

DRUG LIFE CYCLE STAGES:
Research & Development: Preclinical, Clinical (Phase 1, Phase 2, Phase 3)

Drug Substance Production: Primary Process Development, Drug Substance Production

Formulated Drug Production: Dosage Form Development, Dosage Form Production, Packaging, Logistics

SERVICES & CAPABILITIES: Drug Substance: Small Molecule API, Large Molecule Biologics; Drug Product: Oral Solid Dose, Aseptic Fill/Finish, Sterile Injectables, Softgels; Viral Vector Services: preclinical, clinical, commercial; cGMP plasmids; Clinical Trial Services and Logistics

INDIVIDUAL ATTRIBUTE AWARDS: Accessible Senior Management, Innovation, Reputation, State-of-the-Art

CATEGORIES WON:

Vetter Pharma International

Ravensburg, Germany

vetter-pharma.com

Phone: +49 751 37000

Contact: Andrea Wesp

Email: info@vetter-pharma.com

KEY LOCATIONS: Ravensburg, Germany; Langenargen, Germany; Chicago, IL, USA; Rankweil, Austria

DRUG TYPE:
Biopharmaceuticals, Pharmaceuticals

DRUG LIFE CYCLE STAGES:
Research & Development: Preclinical, Clinical (Phase 1, Phase 2, Phase 3)

Formulated Drug Production: Dosage Form Development, Dosage Form Production, Packaging, Logistics

SERVICES & CAPABILITIES: Drug Product Development, Aseptic Filling and Visual Inspection, Device Assembly and Packaging, Analytical Services, Regulatory Support, Logistic Service.

INDIVIDUAL ATTRIBUTE AWARDS: Innovation, On-Time Delivery, Reputation, Right First Time, State-of-the-Art, Strength of Science

CATEGORIES WON:

WuXi Biologics

Wuxi, Jiangsu Province, China

wuxibiologics.com

Phone: +86 (21) 2006-3734

Contact: Angus Turner

Email: angus.turner@wuxibiologics.com

KEY LOCATIONS: Wuxi, Shanghai, Hangzhou and Suzhou, China; Dundalk, Ireland; Wuppertal and Leverkusen, Germany; Cranbury, NJ, USA

DRUG TYPE:
Biopharmaceuticals

DRUG LIFE CYCLE STAGES:
Research & Development: Discovery, Preclinical, Clinical (Phase 1, Phase 2, Phase 3)

Drug Substance Production: Primary Process Development, Drug Substance Production

Formulated Drug Production: Dosage Form Development, Dosage Form Production, Packaging, Logistics

SERVICES & CAPABILITIES: We offer a true single-source, fully integrated discovery, development, and manufacturing platform for biologics from mammalian and microbial expression systems with industry-leading timelines to IND and BLA, and nine GMP facilities certified by global regulatory agencies.

INDIVIDUAL ATTRIBUTE AWARDS: Accessible Senior Management, Innovation, On-Time Delivery, Reputation, Right First Time, State-of-the-Art, Strength of Science

CATEGORIES WON:

WuXi STA, a subsidiary of WuXi AppTec

Shanghai, China

stapharma.com

Contact: Lynne Faust

Email: Lynne.Faust@wuxiapptec.com

KEY LOCATIONS: Changzhou, Jiangsu, China; Couvet, Neuchâtel, Switzerland; Middletown, DE, USA; Shanghai Waigaoqiao, China; Taixing, Jiangsu, China; Wuxi City, Jiangsu, China

DRUG TYPE:
Pharmaceuticals

DRUG LIFE CYCLE STAGES:
Research & Development: Discovery, Preclinical, Clinical (Phase 1, Phase 2, Phase 3)

Drug Substance Production: Primary Process Development, Drug Substance Production

Formulated Drug Production: Dosage Form Development, Dosage Form Production, Packaging, Logistics

SERVICES & CAPABILITIES: 1. Small molecule APIs process development and manufacturing; 2. Biocatalysis, Chemo Catalysis, Continuous Processing, Crystallization and Particle Engineering, Preparative HPLC and SFC; 3. High Potency APIs process development and manufacturing (10 ng/m³ OEL limit); 4. Formulation development and drug product manufacturing for both oral and injectable dosage forms; 5. Spray Dried Dispersion, Hot Melt Extrusion, Lipid Nanoparticle, Nano Suspension, Liquid Capsules; 6. High Potency drug product manufacturing for both oral and injectable dosage forms (10 ng/m³ OEL limit); 7. End-to-end LNP Technology; 8. WuXi TIDES, our CRDMO service platform supporting discovery, CMC development, and manufacturing of oligonucleotides, peptides, and their complex chemical conjugates.

INDIVIDUAL ATTRIBUTE AWARDS: Accessible Senior Management, Innovation, On-Time Delivery, Reputation, State-of-the-Art, Strength of Science

Now in its thirteenth year,
Outsourced Pharma's CDMO Leadership Awards
recognize the CDMOs exceeding expectations
as determined by the customers who utilize their services.

CDMO LEADERSHIP AWARDS2024

The Spotlight Shines Brighter When It's The Customer Behind The Lens

PRESENTED BY
OUTSOURCED PHARMA

CONGRATULATIONS TO OUR 2024 WINNERS

- AbbVie
- Ajinomoto Bio-Pharma Services
- Almac Group
- Bachem AG
- Boehringer Ingelheim Biopharmaceuticals
- CARBOGEN AMCIS
- Catalent
- CordenPharma International
- Curia
- Evotec
- FAMAR
- Fareva
- FUJIFILM Diosynth Biotechnologies
- GenScript ProBio USA
- Grifols International
- IDT Biologika
- KBI Biopharma
- MilliporeSigma
- Olon Group
- Pfizer CentreOne
- Piramal Pharma Solutions
- Recipharm
- Resilience
- Samsung Biologics
- Simtra BioPharma Solutions
- Syngene International
- Thermo Fisher Scientific
- Vetter Pharma International
- WuXi Biologics
- WuXi STA, a subsidiary of WuXi AppTec

Brought To You By
LIFE SCIENCE CONNECT

With Research By
ISR reports

OutsourcedPharma.com

SAMSUNG BIOLOGICS

Antibody Drug Conjugates



Link Your Antibody to its Fullest Potential

abbvie | Contract Manufacturing

Vision. Expertise. Success.

Eyecare | Topical | Aseptic Fill-Finish | Hot Melt Extrusion (HME) | Oral Solid Dose
Microbial Fermentation | Biologics | Antibody Drug Conjugate (ADC) | Custom API

AbbVie Contract Manufacturing partners with companies around the globe to develop, scale and manufacture their pharmaceutical products.

With decades of experience, we see the complete picture to deliver your vision and real-world results, while improving people's lives.

CDMO LEADERSHIP AWARDS2024 SERVICE

Start the journey, at abbviecontractmfg.com

Vision. Expertise. Success.